全球62个国家人群水平衰弱患病率的系统综述与荟萃分析
该研究通过系统检索1998年至2020年的观察性人群研究,纳入240项研究、覆盖62个国家和地区、1755497名50岁及以上参与者,评估衰弱的患病率。采用身体衰弱指标的研究合并患病率为12%(95%CI=11-13%),采用衰弱指数(FI)的研究为24%(95%CI=22-26%);衰弱前期患病率分别为46%和49%。女性患病率高于男性,且患病率随研究纳入的最低年龄增加而升高。
要点
- 身体衰弱指标合并患病率12%,衰弱指数模型为24%,两者差异显著。
- 女性衰弱患病率高于男性,身体衰弱指标为15%对11%,FI为29%对20%。
- 仅纳入全国代表性研究时,身体衰弱患病率为7%,FI为24%。
核心结论
- 人群水平衰弱患病率因衰弱分类工具和性别而异,数据异质性大且全国代表性研究有限,难以准确解读地区差异。
研究设计与样本
- 系统综述与荟萃分析,检索PubMed、Embase、CINAHL和Cochrane Library数据库1998年1月1日至2020年4月1日发表的观察性人群研究,纳入50岁及以上个体,使用任意衰弱测量工具,最终纳入240项研究、265个患病率数据、覆盖62个国家和地区、1755497名参与者。
主要发现
- 使用身体衰弱指标的研究合并患病率为12%(95%CI=11-13%;n=178),使用衰弱指数(FI)的研究为24%(95%CI=22-26%;n=71)。
- 衰弱前期患病率在使用身体衰弱指标的研究中为46%(95%CI=45-48%;n=147),在使用FI的研究中为49%(95%CI=46-52%;n=29)。
- 身体衰弱指标下女性患病率为15%(95%CI=14-17%;n=142),男性为11%(95%CI=10-12%;n=144);FI下女性为29%(95%CI=24-35%;n=34),男性为20%(95%CI=16-24%;n=34)。
- 仅分析全国代表性研究时,身体衰弱患病率为7%(95%CI=5-9%;n=46),FI为24%(95%CI=22-26%;n=44)。
- 患病率随研究纳入的最低年龄增加而升高。
关键数值与推荐
- 身体衰弱指标合并患病率12%(95%CI=11-13%),衰弱指数模型合并患病率24%(95%CI=22-26%)。
- 全国代表性研究中身体衰弱患病率7%(95%CI=5-9%),FI患病率24%(95%CI=22-26%)。
临床怎么用
- 老年医学科医生应了解衰弱患病率因评估工具(身体衰弱指标 vs 衰弱指数)和性别而异,在临床中需明确所用工具并考虑性别差异。
- 全国代表性研究数据显示身体衰弱患病率较低(7%),而FI较高(24%),提示不同工具识别的人群不同,临床评估时应结合具体工具解释结果。
局限性
- 数据异质性大,全国代表性研究有限,难以准确解读地理区域差异。
- 需要统一的数据收集方法以提高人群水平患病率估计的准确性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: The prevalence of frailty at population level is unclear. We examined this in population-based studies, investigating sources of heterogeneity. METHODS: PubMed, Embase, CINAHL and Cochrane Library databases were searched for observational population-level studies published between 1 January 1998 and 1 April 2020, including individuals aged ≥50 years, identified using any frailty measure. Prevalence estimates were extracted independently, assessed for bias and analysed using a random-effects model. RESULTS: In total, 240 studies reporting 265 prevalence proportions from 62 countries and territories, representing 1,755,497 participants, were included. Pooled prevalence in studies using physical frailty measures was 12% (95% CI = 11-13%; n = 178), compared with 24% (95% CI = 22-26%; n = 71) for the deficit accumulation model (those using a frailty index, FI). For pre-frailty, this was 46% (95% CI = 45-48%; n = 147) and 49% (95% CI = 46-52%; n = 29), respectively. For physical frailty, the prevalence was higher among females, 15% (95% CI = 14-17%; n = 142), than males, 11% (95% CI = 10-12%; n = 144). For studies using a FI, the prevalence was also higher in females, 29% (95% CI = 24-35%; n = 34) versus 20% (95% CI = 16-24%; n = 34), for males. These values were similar for pre-frailty. Prevalence increased according to the minimum age at study inclusion. Analysing only data from nationally representative studies gave a frailty prevalence of 7% (95% CI = 5-9%; n = 46) for physical frailty and 24% (95% CI = 22-26%; n = 44) for FIs. CONCLUSIONS: Population-level frailty prevalence varied by classification and sex. Data were heterogenous and limited, particularly from nationally representative studies making the interpretation of differences by geographic region challenging. Common methodological approaches to gathering data are required to improve the accuracy of population-level prevalence estimates. PROTOCOL REGISTRATION: PROSPERO-CRD42018105431.
引用
- O'Caoimh R, Sezgin D, O'Donovan MR, et al. Prevalence of frailty in 62 countries across the world: a systematic review and meta-analysis of population-level studies. Age Ageing. 2021. PMID: 33068107. doi:10.1093/ageing/afaa219
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。